Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCS110 With BRAF/MEK Inhibition in Melanoma After Progression on BRAF/MEK Inhibition
NCT03455764Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2018
- Primary completion
- Sep 2023
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of lacnotuzumab in melanoma, sponsored by Dana-Farber Cancer Institute. Started Sep 2018; status: completed.
02
Drugs
lacnotuzumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03455764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03455764.